Get the latest Venture Capital & Angel investors news and info Join Our Mailing List:

Your Name: 

Your Email:  

*By submitting your name & email you agree to receive for FREE our scholarships & offers Newsletters. You agree also with the storage and handling of your data by this website and 3rd party email services.
You may unsubscribe if you wish. And you can delete your email and name at any time by emailing us to the email on the bottom of this page.

Follow us on

Visit the Business Grant Funding.Net site

Business Grant Funding.Net
 
  • Act Venture Capital Ltd

    ACT Venture Capital is Ireland’s leading venture capital firm. Act Venture Capital was founded as an independent operation in 1994. ACT Venture Capital has completed over 70 investments, principally in technology based companies serving global markets.

    ACT takes a stage diversified approach to investing in exceptional companies operating in Information & Communications Technology, Internet & Media, Healthcare and the Development Capital sector.

    By leveraging the collective experience of our investment professionals as well as our extensive network of contacts, ACT takes a value added approach to technology investing. We take an active role in our portfolio companies, through board participation and beyond, to support talented entrepreneurs to achieve success on a world stage.

    ACT has raised over €350 million sourced from leading American, European, Irish and UK institutions. We provide capital to high potential companies located within Ireland, the UK and Europe in the range of €1 million to €15 million.

    Last year, ACT has invested $5.25 Million in Novate Medical Ltd, a privately-held development-stage medical device company based in Galway, Ireland. Novate has completed a €4 Million (approximately $5.25 Million) round of funding. The financing was co led by Dublin based ACT Venture Capital and life science investor Seroba BioVentures, with Enterprise Ireland also participating in the round.

    Novate was formed in 2006 to develop and commercialise a novel technology aimed at the rapidly expanding market for inferior vena cava filters. These products are used as a means of preventing clots reaching the lungs and causing a pulmonary embolism (PE). PE is the third leading cause of acute cardiovascular death in the developed world. It affects over 1.2 million people in the US and Europe annually and accounts for as many as 500,000 deaths per year.

  •  
 

By using this website you agree with our cookie policy